LEGN - NASDAQ
Legend Biotech Corporation
$35.98
+3.1%Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
At a Glance
Live SnapshotLegend Biotech Corporation Management Team
Ms. Caroline LeCates Paul
Associate Director of Investor Relations
Dr. Ying Huang Ph.D.
Chief Executive Officer & Director
Mr. Carlos Santos
Chief Financial Officer
Dr. Mythili Koneru M.D., Ph.D.
Chief Medical Officer
Mr. James Pepin J.D.
General Counsel
Mr. Tim Roberts
Global Compliance Officer
Ms. Jessie Yeung M.B.A.
Interim Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Surabhi Verma
Manager of Investor Relations & Corporate Communications
Mr. Alan S. Bash
President of CARVYKTI®
Dr. Guowei Fang Ph.D.
President of Research & Development
Mr. Birk Vanderweeen
Senior Vice President of Global Manufacturing & Supply
Mr. Shu Wu
Senior Vice President of Global Operations & GM of Legend China
Legend Biotech Corporation Insider Positioning
During the last 12 months, insiders have sold $87K worth of LEGN shares, with no buying activity reported.
3 Months
0
0.00
9.9K
87.14K
-87K
-$87K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Huang Ying
Director, Officer: Chief Executive Officer
$87K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $87K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
1 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.
SEC Filings
LEGN - Filing history and reports
No SEC filings available for LEGN
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.